Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech’s 2008 Meets Expectations, Though AppTec Disappoints

publication date: Mar 26, 2009

WuXi PharmaTech (药明康德) met, but didn’t beat, its 2008 financial guidance goals and admitted that its $151 million AppTec acquisition has not performed up to expectations. WuXi shut down AppTec’s US-based biologics manufacturing operations in December of 2008, saying it did not see any resurgence in that sector. However, AppTec’s biopharma and medical device testing business is continuing. WuXi Chairman and CEO Ge Li blamed AppTec’s disappointing performance on the larger economic crisis, which curtailed demand for contract biologics manufacturing. More details...

Stock Symbol: (NYSE: WX)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here